Chan Hon-Lai, Papazoglou Dimitrios D, Jungi Silvan, Weiss Salome, Becker Daniel, Kotelis Drosos, Makaloski Vladimir
Department of Vascular Surgery, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
J Clin Med. 2023 Jul 15;12(14):4708. doi: 10.3390/jcm12144708.
There is a paucity of reporting outcomes of complex aortic aneurysm treatment such as juxtarenal abdominal aortic aneurysms, where additional techniques to preserve renal artery perfusion are required.
Retrospective analysis of consecutive patients who underwent emergent and elective aortic repair with fenestrated PMEGs between March 2019 and January 2023. Endpoints were technical success, reinterventions, secondary reinterventions and target vessel patency.
Forty-seven target vessels in 37 patients (23 male, median age 75 years) were targeted, of which 44 were renal arteries (RAs) with a mean diameter of 5.4 ± 1.0 mm. Thirteen were accessory RAs and six had a diameter ≤ 4 mm. Technical success rate was 87% overall; 97% for main and 62% for accessory RAs respectively. Target vessel patency and freedom from secondary reintervention was 100% and 97% at 30 days and 96% and 91% at one year, respectively. There was no 30-day mortality.
Fenestrated physician-modified endografts are safe and effective for the treatment of patients with juxtarenal abdominal aortic aneurysms when incorporating main renal arteries. Limited technical success may be expected when targeting accessory renal arteries, especially when small in diameter. Long-term follow-up is needed to confirm durability of PMEGs for renal artery preservation.
诸如肾旁腹主动脉瘤这类复杂主动脉瘤治疗结果的报告较少,此类疾病需要采用额外技术来保留肾动脉灌注。
对2019年3月至2023年1月期间连续接受带开窗的医生改良型血管内移植物进行急诊和择期主动脉修复的患者进行回顾性分析。观察终点为技术成功率、再次干预、二次再次干预和靶血管通畅情况。
37例患者(23例男性,中位年龄75岁)共47条靶血管被纳入研究,其中44条为肾动脉,平均直径5.4±1.0毫米。13条为副肾动脉,6条直径≤4毫米。总体技术成功率为87%;主肾动脉为97%,副肾动脉为62%。靶血管通畅率及无二次再次干预率在30天时分别为100%和97%,在1年时分别为96%和91%。30天内无死亡病例。
当纳入主要肾动脉时,带开窗的医生改良型血管内移植物治疗肾旁腹主动脉瘤患者是安全有效的。针对副肾动脉时,尤其是直径较小时,可能预期技术成功率有限。需要长期随访以确认医生改良型血管内移植物保留肾动脉的耐久性。